Browse > Home / IndustryIntelligence / Technology / Scientific / Development Agreements

Scientific & Technical Instruments

Development Agreements

Page 1 of 11

$43	Preview Full Doc	2003	Manufacturing, Co-Marketing and Development Agreement Manufacturing, Co-Marketing and Development Agreement (38K) Doc #130219: Click preview link for longer preview. MANUFACTURING, CO-MARKETING AND DEVELOPMENT AGREEMENT BETWEEN HYUNDAI AUTONET CO.,LTD AND SMARTIRE SYSTEMS, INC THIS AGREEMENT dated the 6^th of February, 2003. BETWEEN: SmarTire Systems, Inc. (hereafter "SmarTire"), a British Columbia, Canadian corporation, having its principal office at 13151 Vanier Place, Suite 150, Richmond, British Columbia, Canada V6V 2J1, and: Hyundai AUTONET Co., Ltd Corporation (hereafter "HACO"), a Korean corporation, having its principal office at San 136-1, Ami-ri, Bubal-eub, Ichon-si. Kyoungki-do, 467-860, Korea. WHEREAS: SmarTire has been, for many years, engaged in the design, development, and sale of Products for monitoring tire pressure and temperature, and has acquired substantial Technical Information, know-how, experience, Patents, patent Applications, and other intellectual property relating to the Products, and; OEM manufacturers of automobiles plan to evaluate the Products for use in their automobiles, and; SmarTire desires a relationship with a Tier 1 Supplier who has knowledge relating to the manufacture, supply, quality and logistics of providing Products to the Korean OEM market and Korean after-market, and; SmarTire has selected HACO as a Tier 1 Supplier to provide its Products to the Korean OEM industry, and; HACO believes that it can introduce SmarTire's Products to OEM Customers that do not have a current relationship with SmarTire, and will help to introduce the Products and secure sales for the Products, and HACO and SmarTire plan to participate in the re-engineering of certain Products to reduce their cost and suitability for OEM and after-market customers, and SmarTire wishes to grant HACO a license to manufacture and supply the Products to Korean OEM and After-Market Customers. 2 NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, the SmarTire and HACO agree as follows: 130219	SmarTire SmarTire Systems, Inc. ( Scientific & Technical Instruments ) As referenced in this Manufacturing, Co-Marketing and Development Agreement: SMARTIRE SYSTEMS, INC – Technologies EX-10 7 smrtagt.htm 10.47 Exhibit 10.47 1 <R></R> MANUFACTURING, CO-MARKETING AND DEVELOPMENT AGREEMENT BETWEEN HYUNDAI AUTONET CO.,LTD AND SMARTIRE SYSTEMS, INC THIS AGREEMENT dated the 6th of February, 2003. BETWEEN: SmarTire Systems, Inc. (hereafter "SmarTire"), a British Columbia, Canadian corporation, having its principal office at 13151 Vanier Place, Suite 150, _____________ SmarTire Systems, Inc. – lt;R></R> MANUFACTURING, CO-MARKETING AND DEVELOPMENT AGREEMENT BETWEEN HYUNDAI AUTONET CO.,LTD AND SMARTIRE SYSTEMS, INC THIS AGREEMENT dated the 6th of February, 2003. BETWEEN: SmarTire Systems, Inc. (hereafter "SmarTire"), a British Columbia, Canadian corporation, having its principal office at 13151 Vanier Place, Suite 150, Richmond, British Columbia, Canada V6V 2J1, and: Hyundai AUTONET Co., Ltd Corporation ( _____________ dt 1321890 ; SmarTire SmarTire Systems, Inc. ( Scientific & Technical Instruments ) As referenced in this Manufacturing, Co-Marketing and Development Agreement: SMARTIRE SYSTEMS, INC – Technologies EX-10 7 smrtagt.htm 10.47 Exhibit 10.47 1 <R></R> MANUFACTURING, CO-MARKETING AND DEVELOPMENT AGREEMENT BETWEEN HYUNDAI AUTONET CO.,LTD AND SMARTIRE SYSTEMS, INC THIS AGREEMENT dated the 6th of February, 2003. BETWEEN: SmarTire Systems, Inc. (hereafter "SmarTire"), a British Columbia, Canadian corporation, having its principal office at 13151 Vanier Place, Suite 150, _____________ SmarTire Systems, Inc. – lt;R></R> MANUFACTURING, CO-MARKETING AND DEVELOPMENT AGREEMENT BETWEEN HYUNDAI AUTONET CO.,LTD AND SMARTIRE SYSTEMS, INC THIS AGREEMENT dated the 6th of February, 2003. BETWEEN: SmarTire Systems, Inc. (hereafter "SmarTire"), a British Columbia, Canadian corporation, having its principal office at 13151 Vanier Place, Suite 150, Richmond, British Columbia, Canada V6V 2J1, and: Hyundai AUTONET Co., Ltd Corporation ( _____________ dt 1321930 ;	Hyundai Autonet Co., Ltd.
$37	Preview Full Doc	2002	Research & Development Agreement Research & Development Agreement (54K) Doc #147648: Click preview link for longer preview. RESEARCH & DEVELOPMENT AGREEMENT Between: Roche Diagnostics GmbH Sandhofer Strasse 16 68305 Mannheim Federal Republic of Germany (hereinafter referred to as "RDG") and CombiMatrix Corporation 6500 Harbour Heights Pkwy. Mukilteo, WA 98275 USA - hereinafter referred as to "CBMX" {PAGE} C O N F I D E N T I A L -2- This Research & Development Agreement ("Agreement"), is made and entered into by and between RDG and CBMX. RDG and CBMX may be referred to herein individually as a "Party" and collectively as the "Parties." RECITALS WHEREAS: (1) CBMX and RDG have entered into a broad strategic collaboration in nucleic acid microarray technology comprising a License & Supply Agreement and a Research & Development Agreement on July 1st 2001. (2) Due to changes in CBMX business model for the collaboration the Parties have decided to reformulate their mutual relationship with this Agreement dated as of July 1st 2002 which shall replace in its entirety, including all existing amendments, such Research and Development Agreement of July 1st 2001 and with a new License Agreement (the "License Agreement") which replaces in its entirety the existing License and Supply Agreement dated July 1st 2001 and is signed concurrently with this Agreement. (3) CBMX shall develop for RDG under the terms and conditions of this Agreement prototypes and products. 1. DEFINITIONS 1.1 Capitalised terms in this Agreement shall have the same meaning as in the License Agreement unless defined otherwise in this Agreement. The following terms shall have the following meaning: (1) "Agreement" shall mean this Research and Development Agreement and all Annexes hereto. (2) "Chiplettes" shall mean smaller (in size) Chips (with Chips being generally about * cm2 or larger) that have Content synthesized prior to dicing to Chiplette size (approximately * cm2 or smaller) and do not have separate electrical contact points. (3) "Development Program" shall mean the development program as attached to this Agreement as ANNEX I for the development of products under this Agreement, which Development Program may Research & Development Agreement, Combimatrix September 25th 2002 * Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote commissions. {PAGE} C O N F I D E N T I A L -3- be amended from time to time by the Parties in the Development Steering Committee as set forth herein. (4) "Development Steering Committee or DSC" shall mean a group of technical and business representatives from RDG and CBMX responsible for managing the Development Program and the R&D collaboration under this Agreement as detailed in Section 3 of this Agreement. (5) "Development and Payment Schedule" shall mean the time schedule for the development and payments based on milestones as attached to this Agreement as ANNEX I. (6) "Effective Date" shall mean the effective date of a settlement of the law suit between CBMX and its employee Donald Montgomery on one side and Nanogen, Inc, of San Diego, California on the other side at the United States District Court, Southern District of California; Case No.: CV2369 JM RBB, in which settlement Nanogen irrevocably confirms and accepts CBMX sole ownership to U.S. Patents 6,093,302 and 6,280,595 and covenants not to sue or make any claim against CBMX in the future regarding CBMX legitimate ownership of U.S. Patents 6,093,302 and 6,280,595. (7) "Miniarrays" shall mean smaller (in size) Chips (with Chips being generally ) that are . (8) "Mono-Cassette" shall have the meaning set forth in the License Agreement. (9) "Results" shall mean any and all results (including but not limited to products, inventions, data, Know-How, Software, ideas and other expertise) developed under the Development Program and to be delivered to RDG, whether patentable or not. (10) "Specifications" shall mean the general specifications for all Deliverables and SOP's for functional test of Deliverables preliminarily set forth in Annex II, Attachments 1 - 9 attached hereto and as amended from time to time by the DSC. (11) "Wafer(s)" shall mean the generally circular silicon-based semiconductor product having the circuitry etched thereon and arranged for a plurality of Arrays, Blank Chips, Miniarrays or Chiplettes to be diced out. (12) "Derivative Work" means any RDG developed or funded translation (including any translation into other computer languages), modification, correction, addition, extension, upgrade, improvement, compilation, abridgement or other form in which the Software may be recast, transformed or adapted including but not limited to all forms in which such Derivative Work would infringe any of the copyrights, including audiovisual copyrights, in the Software.. 147648	Nanogen Nanogen, Inc. ( Scientific & Technical Instruments ) As referenced in this Research & Development Agreement: Nanogen, Inc, – Agreement as ANNEX I. (6) "Effective Date" shall mean the effective date of a settlement of the law suit between CBMX and its employee Donald Montgomery on one side and Nanogen, Inc, of San Diego, California on the other side at the United States District Court, Southern District of California; Case No.: CV2369 JM RBB, in which settlement Nanogen irrevocably confirms _____________ dt 1457632 ; Nanogen Nanogen, Inc. ( Scientific & Technical Instruments ) As referenced in this Research & Development Agreement: Nanogen, Inc, – Agreement as ANNEX I. (6) "Effective Date" shall mean the effective date of a settlement of the law suit between CBMX and its employee Donald Montgomery on one side and Nanogen, Inc, of San Diego, California on the other side at the United States District Court, Southern District of California; Case No.: CV2369 JM RBB, in which settlement Nanogen irrevocably confirms _____________ dt 1457674 ; Roche Diagnostics GmbH;	CombiMatrix Corporation; Acacia Research Corp
$33	Preview Full Doc	2003	Joint Development Agreement Joint Development Agreement (7K) Doc #170399: Click preview link for longer preview. JOINT DEVELOPMENT AGREEMENT Invisa, Inc., a Nevada Corporation and its wholly owned subsidiary SmartGate, L.C., a Florida Limited Liability Company ("SmartGate") and Dominator International LTD ("Dominator"), for good and valuable consideration, enter into this Agreement as of this 21st day of July, 2003. 1. INTRODUCTION. SmartGate and Dominator have entered into a joint Confidentiality Agreement protecting the confidentiality of their respective trade secrets and proprietary information. By virtue of this Agreement, both SmartGate and Dominator express interest in cooperating and sharing ideas with each other regarding the potential for Dominator, as a customer of SmartGate, to benefit from SmartGate's proprietary non-contact safety technology. 2. PURPOSE. The purpose of this Agreement is to enable SmartGate and Dominator to have the benefit of an exchange of ideas regarding the potential utilization of SmartGate's non-contact safety technology by Dominator without jeopardizing or adversely affecting their respective rights and interests. Accordingly, this Agreement sets forth the terms and conditions pursuant to which SmartGate and Dominator can, in the exercise of their respective discretion, explore, identify and facilitate the ability of Dominator to utilize and/or integrate the SmartGate non-contact safety technology in its powered closure device products. In entering into this Agreement, neither party assumes nor accepts any obligation, whether contractual or otherwise, to perform any task, or engage in any activity, or assume any financial obligation. Further, by entering into this Agreement, neither SmartGate nor Dominator appoints nor authorizes the other party to serve as an agent or otherwise represent it in any capacity. The parties acknowledge that Dominator has, by virtue of this Agreement, no right or entitlement to use, purchase or benefit from SmartGate's technology and any such right shall be governed by a separate written agreement between the parties. 3. TERM. This Agreement may be terminated by either party upon thirty (30) days' written notice; however, notwithstanding termination, this Agreement shall continue to govern the relationship, rights and obligations of the parties with regard to the actions and disclosures of the parties hereunder, prior to termination. 170399	Invisa Invisa, Inc. ( Scientific & Technical Instruments ) As referenced in this Joint Development Agreement: Invisa, Inc. – {DOCUMENT} {TYPE}EX-10.77 {SEQUENCE}13 {FILENAME}g83979exv10w77.txt {DESCRIPTION}JOINT DEVELOPMENT AGREEMENT {TEXT} {PAGE} EXHIBIT 10.77 JOINT DEVELOPMENT AGREEMENT Invisa, Inc. , a Nevada Corporation and its wholly owned subsidiary SmartGate, L.C., a Florida Limited Liability Company ("SmartGate") and Dominator International LTD ("Dominator"), for good and valuable consideration, enter into _____________ dt 1484174 ; Invisa Invisa, Inc. ( Scientific & Technical Instruments ) As referenced in this Joint Development Agreement: Invisa, Inc. – {DOCUMENT} {TYPE}EX-10.77 {SEQUENCE}13 {FILENAME}g83979exv10w77.txt {DESCRIPTION}JOINT DEVELOPMENT AGREEMENT {TEXT} {PAGE} EXHIBIT 10.77 JOINT DEVELOPMENT AGREEMENT Invisa, Inc. , a Nevada Corporation and its wholly owned subsidiary SmartGate, L.C., a Florida Limited Liability Company ("SmartGate") and Dominator International LTD ("Dominator"), for good and valuable consideration, enter into _____________ dt 1456901 ;	SmartGate, L.C.; Dominator International LTD
$37	Full Doc	2003	Joint Development Agreement Joint Development Agreement (7K) Doc #1112739: This document is immediately available for purchase, but does not have a preview available for viewing. 1112739	Invisa Invisa, Inc. ( Scientific & Technical Instruments ) ;	Invisa Invisa, Inc. ( Scientific & Technical Instruments )
$42	Preview Full Doc	2000	Joint Development Agreement Joint Development Agreement (104K) Doc #1124906: Click preview link for longer preview. JOINT DEVELOPMENT AGREEMENT This Joint Development Agreement ("Agreement") dated as of the _____day of November, 1999 ("Effective Date") is by and between ILLUMINA, INC., a California corporation, located at 9390 Towne Centre Drive, Suite 200, San Diego, CA 92121- 3015 ("Illumina"), and PE CORPORATION, a Delaware corporation, through its PE Biosystems Group, located at 850 Lincoln Centre Drive, Foster City, CA 94404 ("PEB"). Background Illumina has certain skills, proprietary . . . 1124906	Citibank Citibank, NA As referenced in this Joint Development Agreement: Citibank, N.A. – States dollars into United States dollars, the payments will be converted at the closing commercial sell rate of exchange for United States dollars and each currency involved as quoted by Citibank, N.A. , or any successor thereto, in New York on the last business day of the relevant period. 13.5. Severability. If a court or an arbitrator of competent jurisdiction ------------ holds _____________ dt 1479321 ; Illumina Illumina, Inc. ( Scientific & Technical Instruments ) As referenced in this Joint Development Agreement: ILLUMINA, INC. – TEXT> <PAGE> EXHIBIT 10.5 JOINT DEVELOPMENT AGREEMENT This Joint Development Agreement ("Agreement") dated as of the _____day of November, 1999 ("Effective Date") is by and between ILLUMINA, INC. , a California corporation, located at 9390 Towne Centre Drive, Suite 200, San Diego, CA 92121- 3015 ("Illumina"), and PE CORPORATION, a Delaware corporation, through its PE Biosystems Group, located _____________ Illumina, Inc. – refused, unclaimed, or deemed undeliverable by the postal authorities, messenger, or overnight delivery service. 13.11.3. Addresses. Addresses for purpose of giving notice are as --------- follows: If to Illumina: Illumina, Inc. 9390 Towne Centre Drive, Suite 200 San Diego, CA 92121-3015 FAX No.: 858-587-4297 Attn.: President If to PEB PE Biosystems 850 Lincoln Centre Drive Foster City, _____________ ILLUMINA, INC. – No.: 650-638-6677 Attn.: President, PE Biosystems [Signature Page Follows] 30 <PAGE> The Parties , through their authorized officers, have executed this Agreement as of the Effective Date. ILLUMINA, INC. PE CORPORATION, THROUGH ITS PE BIOSYSTEMS GROUP By: _______________________________ By: _______________________________ Name: _____________________________ Name: _____________________________ Title: ____________________________ Title: ____________________________ Date: _____________________________ Date: _____________________________ 31 <PAGE> EXHIBIT 1 _____________ dt 1468883 ;	Illumina Illumina, Inc. ( Scientific & Technical Instruments ) As referenced in this Joint Development Agreement: ILLUMINA, INC. – TEXT> <PAGE> EXHIBIT 10.5 JOINT DEVELOPMENT AGREEMENT This Joint Development Agreement ("Agreement") dated as of the _____day of November, 1999 ("Effective Date") is by and between ILLUMINA, INC. , a California corporation, located at 9390 Towne Centre Drive, Suite 200, San Diego, CA 92121- 3015 ("Illumina"), and PE CORPORATION, a Delaware corporation, through its PE Biosystems Group, located _____________ Illumina, Inc. – refused, unclaimed, or deemed undeliverable by the postal authorities, messenger, or overnight delivery service. 13.11.3. Addresses. Addresses for purpose of giving notice are as --------- follows: If to Illumina: Illumina, Inc. 9390 Towne Centre Drive, Suite 200 San Diego, CA 92121-3015 FAX No.: 858-587-4297 Attn.: President If to PEB PE Biosystems 850 Lincoln Centre Drive Foster City, _____________ ILLUMINA, INC. – No.: 650-638-6677 Attn.: President, PE Biosystems [Signature Page Follows] 30 <PAGE> The Parties , through their authorized officers, have executed this Agreement as of the Effective Date. ILLUMINA, INC. PE CORPORATION, THROUGH ITS PE BIOSYSTEMS GROUP By: _______________________________ By: _______________________________ Name: _____________________________ Name: _____________________________ Title: ____________________________ Title: ____________________________ Date: _____________________________ Date: _____________________________ 31 <PAGE> EXHIBIT 1 _____________ dt 1483508 ; Citibank Citibank, NA ( Financial ) As referenced in this Joint Development Agreement: Citibank, N.A. – States dollars into United States dollars, the payments will be converted at the closing commercial sell rate of exchange for United States dollars and each currency involved as quoted by Citibank, N.A. , or any successor thereto, in New York on the last business day of the relevant period. 13.5. Severability. If a court or an arbitrator of competent jurisdiction ------------ holds _____________ dt 1479321
$34	Preview Full Doc	2003	Development Agreement Development Agreement (31K) Doc #1132632: Click preview link for longer preview. DEVELOPMENT AGREEMENT BETWEEN VANSCO LTD AND SMARTIRE SYSTEMS, INC THIS AGREEMENT dated the 12 of September, 2003. BETWEEN: SmarTire Systems, Inc. (hereafter "SmarTire"), a Yukon Territory corporation, having its principal office at 13151 Vanier Place, Suite 150, Richmond, British Columbia, Canada V6V 2J1, and: Vansco Electronics Ltd. (hereafter "Vansco"), a Canadian corporation having its principal office at 1305 Clarence Avenue, Winnipeg, Manitoba, R3T 1T4. WHEREAS: a) SmarTire is engaged in the design, development, and sale of Products for monitoring tire pressure and temperature, . . . 1132632	SmarTire SmarTire Systems, Inc. ( Scientific & Technical Instruments ) As referenced in this Development Agreement: SMARTIRE SYSTEMS, INC – Exhibit 10 EX-10 4 exhibit1022f10qsboct.htm EXHIBIT 10.22 Exhibit 10.22 DEVELOPMENT AGREEMENT BETWEEN VANSCO LTD AND SMARTIRE SYSTEMS, INC THIS AGREEMENT dated the 12 of September, 2003. BETWEEN: SmarTire Systems, Inc. (hereafter "SmarTire"), a Yukon Territory corporation, having its principal office at 13151 Vanier Place, Suite 150, Richmond, _____________ SmarTire Systems, Inc. – 10 EX-10 4 exhibit1022f10qsboct.htm EXHIBIT 10.22 Exhibit 10.22 DEVELOPMENT AGREEMENT BETWEEN VANSCO LTD AND SMARTIRE SYSTEMS, INC THIS AGREEMENT dated the 12 of September, 2003. BETWEEN: SmarTire Systems, Inc. (hereafter "SmarTire"), a Yukon Territory corporation, having its principal office at 13151 Vanier Place, Suite 150, Richmond, British Columbia, Canada V6V 2J1, and: Vansco Electronics Ltd. (hereafter "Vansco"), a _____________ dt 1321911 ;	SmarTire SmarTire Systems, Inc. ( Scientific & Technical Instruments ) As referenced in this Development Agreement: SMARTIRE SYSTEMS, INC – Exhibit 10 EX-10 4 exhibit1022f10qsboct.htm EXHIBIT 10.22 Exhibit 10.22 DEVELOPMENT AGREEMENT BETWEEN VANSCO LTD AND SMARTIRE SYSTEMS, INC THIS AGREEMENT dated the 12 of September, 2003. BETWEEN: SmarTire Systems, Inc. (hereafter "SmarTire"), a Yukon Territory corporation, having its principal office at 13151 Vanier Place, Suite 150, Richmond, _____________ SmarTire Systems, Inc. – 10 EX-10 4 exhibit1022f10qsboct.htm EXHIBIT 10.22 Exhibit 10.22 DEVELOPMENT AGREEMENT BETWEEN VANSCO LTD AND SMARTIRE SYSTEMS, INC THIS AGREEMENT dated the 12 of September, 2003. BETWEEN: SmarTire Systems, Inc. (hereafter "SmarTire"), a Yukon Territory corporation, having its principal office at 13151 Vanier Place, Suite 150, Richmond, British Columbia, Canada V6V 2J1, and: Vansco Electronics Ltd. (hereafter "Vansco"), a _____________ dt 1321940
$32	Full Doc	2002	Joint Development Agreement Joint Development Agreement (32K) Doc #1133884: This document is immediately available for purchase, but does not have a preview available for viewing. 1133884	Hydrogenics Hydrogenics Corp. ( Scientific & Technical Instruments )
$43	Preview Full Doc	2006	Development Agreement Development Agreement (55K) Doc #1135291: Click preview link for longer preview. DEVELOPMENT AGREEMENT This Development Agreement (ï¿½Agreementï¿½) is entered into as of this of December 2005 by and between PRINCETON BIOMEDITECH CORPORATION, a New Jersey Corporation (ï¿½PBMï¿½), having its principal place of business at 4242 U.S. Route 1, Monmouth Junction, New Jersey 08852, and NANOGEN, INC., a Delaware Corporation (ï¿½NANOGENï¿½), having its principal place of business at 10398 Pacific Center Court, San Diego, California 92121. RECITALS A. PBM and SYN-X Pharma, Inc., an Ontario Corporation (SYNX), having its principal place of business at 1 Marmac . . . 1135291	Nanogen Nanogen, Inc. ( Scientific & Technical Instruments ) As referenced in this Development Agreement: NANOGEN, INC. – 2005 by and between PRINCETON BIOMEDITECH CORPORATION, a New Jersey Corporation (PBM), having its principal place of business at 4242 U.S. Route 1, Monmouth Junction, New Jersey 08852, and NANOGEN, INC. , a Delaware Corporation (NANOGEN), having its principal place of business at 10398 Pacific Center Court, San Diego, California 92121. RECITALS A. PBM and SYN-X Pharma, Inc., an Ontario _____________ NANOGEN, INC. – by facsimile. IN WITNESS WHEREOF, the Parties have executed this Agreement effective the date first set forth above. PRINCETON BIOMEDITECH CORPORATION By: Name: Jemo Kang Title: President, Chief Executive Officer NANOGEN, INC. By: Name: David Ludvigson Title: President, Chief Operating Officer 22 Exhibit A PBM Patent Portfolio One-Step, Rapid Immunoassay on lateral flow membrane U.S. Patent 5,656,448 _____________ dt 1457637 ;	Nanogen Nanogen, Inc. ( Scientific & Technical Instruments ) As referenced in this Development Agreement: NANOGEN, INC. – 2005 by and between PRINCETON BIOMEDITECH CORPORATION, a New Jersey Corporation (PBM), having its principal place of business at 4242 U.S. Route 1, Monmouth Junction, New Jersey 08852, and NANOGEN, INC. , a Delaware Corporation (NANOGEN), having its principal place of business at 10398 Pacific Center Court, San Diego, California 92121. RECITALS A. PBM and SYN-X Pharma, Inc., an Ontario _____________ NANOGEN, INC. – by facsimile. IN WITNESS WHEREOF, the Parties have executed this Agreement effective the date first set forth above. PRINCETON BIOMEDITECH CORPORATION By: Name: Jemo Kang Title: President, Chief Executive Officer NANOGEN, INC. By: Name: David Ludvigson Title: President, Chief Operating Officer 22 Exhibit A PBM Patent Portfolio One-Step, Rapid Immunoassay on lateral flow membrane U.S. Patent 5,656,448 _____________ dt 1457677
$44	Preview Full Doc	2001	Collaborative Research and Development Agreement Collaborative Research and Development Agreement (73K) Doc #1135622: Click preview link for longer preview. BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.] COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT By and Between HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG and NANOGEN, INC. December 3, 1998 <PAGE> TABLE OF CONTENTS <TABLE> <CAPTION> . . . 1135622	Citibank Citibank, NA As referenced in this Collaborative Research and Development Agreement: Citibank N.A. – With respect to capital acquisitions not financed by Nanogen with specific borrowing, the financing charge will be based on the prime lending rate in effect from time to time at Citibank N.A. , New York, New York, plus two (2) percentage points, to the extent permitted by applicable law, applied to Nanogen's net book value. "Net book value" is defined as _____________ dt 1479338 ; Nanogen Nanogen, Inc. ( Scientific & Technical Instruments ) As referenced in this Collaborative Research and Development Agreement: NANOGEN, INC. – AGREEMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.] COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT By and Between HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG and NANOGEN, INC. December 3, 1998 <PAGE> TABLE OF CONTENTS <TABLE> <CAPTION> PAGE <C> <C> 1. Definitions.........................................................3 2. Research Program....................................................7 _____________ NANOGEN, INC. – between HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG, a German company, having a place of business at D-65926 Frankfurt am Main, Germany (hereinafter, "HR&T"), and NANOGEN, INC. , a Delaware corporation, having its principal office and place of business at 10398 Pacific Center Court, San Diego, California 92121 (hereinafter, "Nanogen"). W I T N E S S _____________ Nanogen, Inc. – of appropriate written 14 <PAGE> confirmation) or sent by registered or certified mail, return receipt requested, or by overnight courier service, postage prepaid as follows: If to Nanogen: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: Chief Executive Officer Facsimile - (619) 546-7717 with a copy to: Nanogen, Inc. 10398 Pacific Center Court San Diego, California _____________ Nanogen, Inc. – service, postage prepaid as follows: If to Nanogen: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: Chief Executive Officer Facsimile - (619) 546-7717 with a copy to: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: General Counsel Facsimile - (619) 546-7717 and if to HR&T: Hoechst Research & Technology Deutschland GmbH & Co _____________ NANOGEN, INC. – all of which together shall constitute one instrument. 17 <PAGE> IN WITNESS WHEREOF, the parties have executed this Agreement through duly authorized representatives as of the Effective Date. NANOGEN, INC. HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG By /s/ HOWARD C. BIRNDORF By /s/ DR. REINER HENNIG ------------------------------------- -------------------------- Howard C. Birndorf President Chairman and Chief Executive Officer By / _____________ dt 1457659 ;	Nanogen Nanogen, Inc. ( Scientific & Technical Instruments ) As referenced in this Collaborative Research and Development Agreement: NANOGEN, INC. – AGREEMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.] COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT By and Between HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG and NANOGEN, INC. December 3, 1998 <PAGE> TABLE OF CONTENTS <TABLE> <CAPTION> PAGE <C> <C> 1. Definitions.........................................................3 2. Research Program....................................................7 _____________ NANOGEN, INC. – between HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG, a German company, having a place of business at D-65926 Frankfurt am Main, Germany (hereinafter, "HR&T"), and NANOGEN, INC. , a Delaware corporation, having its principal office and place of business at 10398 Pacific Center Court, San Diego, California 92121 (hereinafter, "Nanogen"). W I T N E S S _____________ Nanogen, Inc. – of appropriate written 14 <PAGE> confirmation) or sent by registered or certified mail, return receipt requested, or by overnight courier service, postage prepaid as follows: If to Nanogen: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: Chief Executive Officer Facsimile - (619) 546-7717 with a copy to: Nanogen, Inc. 10398 Pacific Center Court San Diego, California _____________ Nanogen, Inc. – service, postage prepaid as follows: If to Nanogen: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: Chief Executive Officer Facsimile - (619) 546-7717 with a copy to: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: General Counsel Facsimile - (619) 546-7717 and if to HR&T: Hoechst Research & Technology Deutschland GmbH & Co _____________ NANOGEN, INC. – all of which together shall constitute one instrument. 17 <PAGE> IN WITNESS WHEREOF, the parties have executed this Agreement through duly authorized representatives as of the Effective Date. NANOGEN, INC. HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG By /s/ HOWARD C. BIRNDORF By /s/ DR. REINER HENNIG ------------------------------------- -------------------------- Howard C. Birndorf President Chairman and Chief Executive Officer By / _____________ dt 1457698 ; Citibank Citibank, NA ( Financial ) As referenced in this Collaborative Research and Development Agreement: Citibank N.A. – With respect to capital acquisitions not financed by Nanogen with specific borrowing, the financing charge will be based on the prime lending rate in effect from time to time at Citibank N.A. , New York, New York, plus two (2) percentage points, to the extent permitted by applicable law, applied to Nanogen's net book value. "Net book value" is defined as _____________ dt 1479338
$37	Preview Full Doc	2000	Collaborative Research and Development Agreement Collaborative Research and Development Agreement (63K) Doc #1135655: Click preview link for longer preview. BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.] COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT By and Between HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG and NANOGEN, INC. December 3, 1998 <PAGE> TABLE OF CONTENTS <TABLE> <CAPTION> . . . 1135655	Citibank Citibank, NA As referenced in this Collaborative Research and Development Agreement: Citibank N.A. – With respect to capital acquisitions not financed by Nanogen with specific borrowing, the financing charge will be based on the prime lending rate in effect from time to time at Citibank N.A. , New York, New York, plus two (2) percentage points, to the extent permitted by applicable law, applied to Nanogen's net book value. "Net book value" is defined as _____________ dt 1479339 ; Nanogen Nanogen, Inc. ( Scientific & Technical Instruments ) As referenced in this Collaborative Research and Development Agreement: NANOGEN, INC. – AGREEMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.] COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT By and Between HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG and NANOGEN, INC. December 3, 1998 <PAGE> TABLE OF CONTENTS <TABLE> <CAPTION> PAGE <S> <C> 1. Definitions.........................................................3 2. Research Program....................................................7 _____________ NANOGEN, INC. – between HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG, a German company, having a place of business at D-65926 Frankfurt am Main, Germany (hereinafter, "HR&T"), and NANOGEN, INC. , a Delaware corporation, having its principal office and place of business at 10398 Pacific Center Court, San Diego, California 92121 (hereinafter, "Nanogen"). W I T N E S S _____________ Nanogen, Inc. – of appropriate written 14 <PAGE> confirmation) or sent by registered or certified mail, return receipt requested, or by overnight courier service, postage prepaid as follows: If to Nanogen: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: Chief Executive Officer Facsimile - (619) 546-7717 with a copy to: Nanogen, Inc. 10398 Pacific Center Court San Diego, California _____________ Nanogen, Inc. – service, postage prepaid as follows: If to Nanogen: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: Chief Executive Officer Facsimile - (619) 546-7717 with a copy to: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: General Counsel Facsimile - (619) 546-7717 and if to HR&T: Hoechst Research & Technology Deutschland GmbH & Co _____________ NANOGEN, INC. – all of which together shall constitute one instrument. 17 <PAGE> IN WITNESS WHEREOF, the parties have executed this Agreement through duly authorized representatives as of the Effective Date. NANOGEN, INC. HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG By /S/ HOWARD C. BIRNDORF By /S/ DR. REINER HENNIG ------------------------------------- -------------------------- Howard C. Birndorf President Chairman and Chief Executive Officer By / _____________ dt 1457663 ;	Nanogen Nanogen, Inc. ( Scientific & Technical Instruments ) As referenced in this Collaborative Research and Development Agreement: NANOGEN, INC. – AGREEMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.] COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT By and Between HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG and NANOGEN, INC. December 3, 1998 <PAGE> TABLE OF CONTENTS <TABLE> <CAPTION> PAGE <S> <C> 1. Definitions.........................................................3 2. Research Program....................................................7 _____________ NANOGEN, INC. – between HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG, a German company, having a place of business at D-65926 Frankfurt am Main, Germany (hereinafter, "HR&T"), and NANOGEN, INC. , a Delaware corporation, having its principal office and place of business at 10398 Pacific Center Court, San Diego, California 92121 (hereinafter, "Nanogen"). W I T N E S S _____________ Nanogen, Inc. – of appropriate written 14 <PAGE> confirmation) or sent by registered or certified mail, return receipt requested, or by overnight courier service, postage prepaid as follows: If to Nanogen: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: Chief Executive Officer Facsimile - (619) 546-7717 with a copy to: Nanogen, Inc. 10398 Pacific Center Court San Diego, California _____________ Nanogen, Inc. – service, postage prepaid as follows: If to Nanogen: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: Chief Executive Officer Facsimile - (619) 546-7717 with a copy to: Nanogen, Inc. 10398 Pacific Center Court San Diego, California 92121 Attn: General Counsel Facsimile - (619) 546-7717 and if to HR&T: Hoechst Research & Technology Deutschland GmbH & Co _____________ NANOGEN, INC. – all of which together shall constitute one instrument. 17 <PAGE> IN WITNESS WHEREOF, the parties have executed this Agreement through duly authorized representatives as of the Effective Date. NANOGEN, INC. HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO KG By /S/ HOWARD C. BIRNDORF By /S/ DR. REINER HENNIG ------------------------------------- -------------------------- Howard C. Birndorf President Chairman and Chief Executive Officer By / _____________ dt 1457702 ; Citibank Citibank, NA ( Financial ) As referenced in this Collaborative Research and Development Agreement: Citibank N.A. – With respect to capital acquisitions not financed by Nanogen with specific borrowing, the financing charge will be based on the prime lending rate in effect from time to time at Citibank N.A. , New York, New York, plus two (2) percentage points, to the extent permitted by applicable law, applied to Nanogen's net book value. "Net book value" is defined as _____________ dt 1479339
$39	Preview Full Doc	2005	License and Development Agreement License and Development Agreement (115K) Doc #1177228: Click preview link for longer preview. LICENSE AND DEVELOPMENT AGREEMENT THIS LICENSE AND DEVELOPMENT AGREEMENT is made as of December 30, 2004 (the "Effective Date") by and between MICROVISION, INC., a corporation organized under the laws of the state of Delaware (hereinafter referred to as "MVIS"), and ETHICON ENDO-SURGERY, INC., a wholly-owned subsidiary of Johnson & Johnson, and a corporation organized under the laws of Ohio (hereinafter referred to as "Ethicon"). Each of Ethicon and MVIS may hereafter be referred to as a "Party" or collectively as "Parties." WHEREAS, MVIS and Ethicon entered into a Technology . . . 1177228	Microvision Microvision, Inc. ( Scientific & Technical Instruments ) As referenced in this License and Development Agreement: MICROVISION, INC. – AND DEVELOPMENT AGREEMENT Exhibit 10.29 Execution Copy LICENSE AND DEVELOPMENT AGREEMENT THIS LICENSE AND DEVELOPMENT AGREEMENT is made as of December 30, 2004 (the "Effective Date") by and between MICROVISION, INC. , a corporation organized under the laws of the state of Delaware (hereinafter referred to as "MVIS"), and ETHICON ENDO-SURGERY, INC., a wholly-owned subsidiary of Johnson & Johnson, _____________ Microvision, Inc. – with respect to which such Notice is given, and (ii) the relevant time period, if any, in which the Party receiving the Notice must respond. If to MVIS by mail: Microvision, Inc. P.O. Box 3008 Bothell, WA 98041-3008 Attention: Office of General Counsel Fax: 425-398-6501 If by overnight courier: Microvision, Inc. 19910 North Creek Parkway Bothell, WA _____________ Microvision, Inc. – must respond. If to MVIS by mail: Microvision, Inc. P.O. Box 3008 Bothell, WA 98041-3008 Attention: Office of General Counsel Fax: 425-398-6501 If by overnight courier: Microvision, Inc. 19910 North Creek Parkway Bothell, WA 98011 Attention: Office of General Counsel Fax: 425-398-6501 with a copy to: Ropes & Gray, LLP One International Place Boston, MA _____________ Microvision, Inc. – IN WITNESS WHEREOF, Ethicon and MVIS intending legally to be bound hereby have caused this LICENSE AND DEVELOPMENT AGREEMENT to be duly executed as of the date first above written. Microvision, Inc. By: _/s/ Richard F. Rutkowski_______ Name: Richard F. Rutkowski Title: CEO Ethicon Endo-Surgery, Inc. By: __/s/ Jeffrey A. Mailler__________ Name: Jeffrey A. Mailler Title: Vice President, _____________ dt 1469094 ;	Microvision Microvision, Inc. ( Scientific & Technical Instruments ) As referenced in this License and Development Agreement: MICROVISION, INC. – AND DEVELOPMENT AGREEMENT Exhibit 10.29 Execution Copy LICENSE AND DEVELOPMENT AGREEMENT THIS LICENSE AND DEVELOPMENT AGREEMENT is made as of December 30, 2004 (the "Effective Date") by and between MICROVISION, INC. , a corporation organized under the laws of the state of Delaware (hereinafter referred to as "MVIS"), and ETHICON ENDO-SURGERY, INC., a wholly-owned subsidiary of Johnson & Johnson, _____________ Microvision, Inc. – with respect to which such Notice is given, and (ii) the relevant time period, if any, in which the Party receiving the Notice must respond. If to MVIS by mail: Microvision, Inc. P.O. Box 3008 Bothell, WA 98041-3008 Attention: Office of General Counsel Fax: 425-398-6501 If by overnight courier: Microvision, Inc. 19910 North Creek Parkway Bothell, WA _____________ Microvision, Inc. – must respond. If to MVIS by mail: Microvision, Inc. P.O. Box 3008 Bothell, WA 98041-3008 Attention: Office of General Counsel Fax: 425-398-6501 If by overnight courier: Microvision, Inc. 19910 North Creek Parkway Bothell, WA 98011 Attention: Office of General Counsel Fax: 425-398-6501 with a copy to: Ropes & Gray, LLP One International Place Boston, MA _____________ Microvision, Inc. – IN WITNESS WHEREOF, Ethicon and MVIS intending legally to be bound hereby have caused this LICENSE AND DEVELOPMENT AGREEMENT to be duly executed as of the date first above written. Microvision, Inc. By: _/s/ Richard F. Rutkowski_______ Name: Richard F. Rutkowski Title: CEO Ethicon Endo-Surgery, Inc. By: __/s/ Jeffrey A. Mailler__________ Name: Jeffrey A. Mailler Title: Vice President, _____________ dt 1469117
$47	Preview Full Doc	2003	Technology Development Agreement Technology Development Agreement (41K) Doc #1179067: Click preview link for longer preview. TECHNOLOGY DEVELOPMENT AGREEMENT BY AND BETWEEN TWENTE UNIVERSITY AND IMMUNICON CORPORATION i TABLE OF CONTENTS Page ARTICLE 1?DEFINITIONS 1 1.1 "Affiliate" 1 1.2 "Agreement Term" 1 1.3 "Budget" 1 1.4 "Cytodisk Technology" 1 1.5 "Effective Date" 1 1.6 "Field" 1 1.7 "Final Research Report" 1 1.8 . . . 1179067	Immunicon Immunicon Corp. ( Scientific & Technical Instruments )
$54	Preview Full Doc	2007	Development Agreement Development Agreement (74K) Doc #3199060: Click preview link for longer preview. DEVELOPMENT AGREEMENT FOR PANTHER INSTRUMENT SYSTEM THIS AGREEMENT is effective as of the last date of execution hereof (the ï¿½Effective Dateï¿½) and is made by and between Gen-Probe Incorporated, (Gen-Probe) a corporation of the State of Delaware, USA, located at 10210 Genetic Center Drive, San Diego, California 92121-4362 and STRATEC Biomedical Systems AG (ï¿½STRATECï¿½), having its principal place of business at Gewerbestrasse 37, D-75217 Birkenfeld-Graefenhausen, Germany. WHEREAS, Gen-Probe is engaged in the business of designing, . . . 3199060	Gen-Probe Gen-Probe Inc. ( Scientific & Technical Instruments ) ;	Gen-Probe Gen-Probe Inc. ( Scientific & Technical Instruments )